Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00721123 · OUTCOME

Percentage of Participants Classified as Responders by EULAR Response Over Time, Through 264 Weeks

A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis · Source last updated 2013-11-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of Participants
Interval / dispersion
Not reported
Time frame
through 264 Weeks

What was measured

Participants were classified as responders based on a European League Against Rheumatism (EULAR) response of Good or Moderate. Comparing the DAS28 from one patient on two different time points, it is possible to define improvement or response. The EULAR response criteria take into consideration both the first score and the change in score in order to classify them as good response, moderate response or no response. The percentage of participants who were classified as responders was recorded, as posted below.

Analysis population: All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.

Groups in this outcome

Week 24

Participants with scores at 24 weeks post-baseline.

Week 48

Participants with scores at 48 weeks post-baseline.

Week 108

Participants with scores at 108 weeks post-baseline.

Week 156

Participants with scores at 156 weeks post-baseline.

Week 204

Participants with scores at 204 weeks post-baseline.

Week 264

Participants with scores at 264 weeks post-baseline.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Week 24514
Week 48468
Week 108429
Week 156409
Week 204380
Week 264362

Reported measurements

EULAR Good Response
Values in Percentage of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Week 2441.2Not reportedNot reportedNot reportedNot reported
Week 4856.6Not reportedNot reportedNot reportedNot reported
Week 10865.5Not reportedNot reportedNot reportedNot reported
Week 15670.9Not reportedNot reportedNot reportedNot reported
Week 20469.5Not reportedNot reportedNot reportedNot reported
Week 26471.0Not reportedNot reportedNot reportedNot reported
EULAR Moderate Response
Values in Percentage of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Week 2448.1Not reportedNot reportedNot reportedNot reported
Week 4839.1Not reportedNot reportedNot reportedNot reported
Week 10829.8Not reportedNot reportedNot reportedNot reported
Week 15625.9Not reportedNot reportedNot reportedNot reported
Week 20426.8Not reportedNot reportedNot reportedNot reported
Week 26425.1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        41.2
      2. group Id
        OG001
        value
        56.6
      3. group Id
        OG002
        value
        65.5
      4. group Id
        OG003
        value
        70.9
      5. group Id
        OG004
        value
        69.5
      6. group Id
        OG005
        value
        71.0
    title
    EULAR Good Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        48.1
      2. group Id
        OG001
        value
        39.1
      3. group Id
        OG002
        value
        29.8
      4. group Id
        OG003
        value
        25.9
      5. group Id
        OG004
        value
        26.8
      6. group Id
        OG005
        value
        25.1
    title
    EULAR Moderate Response
denoms
  1. counts
    1. group Id
      OG000
      value
      514
    2. group Id
      OG001
      value
      468
    3. group Id
      OG002
      value
      429
    4. group Id
      OG003
      value
      409
    5. group Id
      OG004
      value
      380
    6. group Id
      OG005
      value
      362
    units
    Participants
description
Participants were classified as responders based on a European League Against Rheumatism (EULAR) response of Good or Moderate. Comparing the DAS28 from one patient on two different time points, it is possible to define improvement or response. The EULAR response criteria take into consideration both the first score and the change in score in order to classify them as good response, moderate response or no response. The percentage of participants who were classified as responders was recorded, as posted below.
groups
  1. description
    Participants with scores at 24 weeks post-baseline.
    id
    OG000
    title
    Week 24
  2. description
    Participants with scores at 48 weeks post-baseline.
    id
    OG001
    title
    Week 48
  3. description
    Participants with scores at 108 weeks post-baseline.
    id
    OG002
    title
    Week 108
  4. description
    Participants with scores at 156 weeks post-baseline.
    id
    OG003
    title
    Week 156
  5. description
    Participants with scores at 204 weeks post-baseline.
    id
    OG004
    title
    Week 204
  6. description
    Participants with scores at 264 weeks post-baseline.
    id
    OG005
    title
    Week 264
param Type
NUMBER
population Description
All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.
reporting Status
POSTED
time Frame
through 264 Weeks
title
Percentage of Participants Classified as Responders by EULAR Response Over Time, Through 264 Weeks
type
SECONDARY
unit Of Measure
Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice